Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085994 | 1.00 | CYP3A4 (0.31) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 | |
| SCHEMBL6903888 | 1.00 | CYP3A4 (0.31) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 | |
| SCHEMBL674830 | 0.89 | CYP2D6 (0.38) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 | |
| SCHEMBL7081162 | 0.88 | OPRM1 (0.34) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 | |
| SCHEMBL7088878 | 0.88 | OPRM1 (0.34) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 | |
| SCHEMBL7081826 | 0.88 | OPRM1 (0.34) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 | |
| SCHEMBL6903798 | 0.86 | OPRM1 (0.35) | OPRM1OPRD1CYP2D6CYP19A1DPP8 | |
| SCHEMBL6903028 | 0.86 | OPRM1 (0.35) | OPRM1OPRD1CYP2D6CYP19A1DPP8 | |
| SCHEMBL6905064 | 0.86 | OPRM1 (0.35) | OPRM1OPRD1CYP2D6CYP19A1DPP8 | |
| SCHEMBL5081545 | 0.84 | OPRD1 (0.39) | CYP3A4CYP3A5OPRM1OPRD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423146-A1 | COMPOSITION FOR TREATING PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT ACTIVATING DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | Aventis Pharma S.A. (FR) | 2004-06-02 | — | — | EP | claimed |
| EP-1328269-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND A SIBUTRAMIN FOR TREATING OBESITY | Aventis Pharma S.A. (FR) | 2003-07-23 | — | — | EP | claimed |
| WO-2003018060-A1 | COMPOSITION FOR TREATING PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT ACTIVATING DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN | AVENTIS PHARMA S.A. (FR) | 2003-03-06 | — | — | WO | claimed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | claimed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | claimed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | claimed |
| EP-1328269-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND A SIBUTRAMIN FOR TREATING OBESITY | Aventis Pharma S.A. (FR) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002028346-A2 | ASSOCIATION OF THE CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN, FOR TREATING OBESITY | AVENTIS PHARMA S.A. (FR) | 2002-04-11 | — | — | WO | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |